CY1125102T1 - Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης - Google Patents

Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης

Info

Publication number
CY1125102T1
CY1125102T1 CY20221100249T CY221100249T CY1125102T1 CY 1125102 T1 CY1125102 T1 CY 1125102T1 CY 20221100249 T CY20221100249 T CY 20221100249T CY 221100249 T CY221100249 T CY 221100249T CY 1125102 T1 CY1125102 T1 CY 1125102T1
Authority
CY
Cyprus
Prior art keywords
antigen
lepr
binding fragments
leptin
bind
Prior art date
Application number
CY20221100249T
Other languages
Greek (el)
English (en)
Inventor
Jesper Gromada
Panayiotis Stevis
Judith Altarejos
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57184864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1125102(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY1125102T1 publication Critical patent/CY1125102T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CY20221100249T 2015-10-12 2022-03-31 Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης CY1125102T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562240021P 2015-10-12 2015-10-12
US201662359757P 2016-07-08 2016-07-08
US201662375495P 2016-08-16 2016-08-16
US201662393143P 2016-09-12 2016-09-12
PCT/US2016/056465 WO2017066204A1 (en) 2015-10-12 2016-10-11 Antigen-binding proteins that activate the leptin receptor

Publications (1)

Publication Number Publication Date
CY1125102T1 true CY1125102T1 (el) 2024-02-16

Family

ID=57184864

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100249T CY1125102T1 (el) 2015-10-12 2022-03-31 Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης

Country Status (31)

Country Link
US (6) US10023644B2 (enExample)
EP (2) EP4071173A1 (enExample)
JP (5) JP7034068B2 (enExample)
KR (2) KR20250069979A (enExample)
CN (1) CN108368177B (enExample)
AU (1) AU2016338851B2 (enExample)
CA (1) CA3000215A1 (enExample)
CL (2) CL2018000946A1 (enExample)
CO (1) CO2018003852A2 (enExample)
CY (1) CY1125102T1 (enExample)
DK (1) DK3362477T3 (enExample)
EA (1) EA201890928A1 (enExample)
ES (1) ES2908574T3 (enExample)
HR (1) HRP20220426T8 (enExample)
HU (1) HUE058280T2 (enExample)
IL (3) IL300961B2 (enExample)
LT (1) LT3362477T (enExample)
MX (2) MX2018004531A (enExample)
MY (1) MY187975A (enExample)
PH (1) PH12018500663A1 (enExample)
PL (1) PL3362477T3 (enExample)
PT (1) PT3362477T (enExample)
RS (1) RS63061B1 (enExample)
SG (1) SG10201913432RA (enExample)
SI (1) SI3362477T1 (enExample)
SM (1) SMT202200125T1 (enExample)
TW (3) TW202417497A (enExample)
UA (1) UA124419C2 (enExample)
UY (1) UY36942A (enExample)
WO (1) WO2017066204A1 (enExample)
ZA (1) ZA201801975B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145206A1 (en) 2015-03-10 2016-09-15 Regeneron Pharmaceuticals, Inc. Aseptic piercing system and method
TW202417497A (zh) * 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
EA201991075A1 (ru) * 2016-11-08 2019-10-31 Антигенсвязывающие белки, которые проявляют антагонизм в отношении лептинового рецептора
ES2919934T3 (es) 2017-05-05 2022-07-29 Regeneron Pharma Autoinyector y procedimientos de uso relacionados
KR20200100089A (ko) * 2017-12-18 2020-08-25 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체 및/또는 gp130에 결합하는 이중 특이적 항원 결합 분자 및 이의 사용 방법
LT3773713T (lt) * 2018-04-06 2025-08-25 Regeneron Pharmaceuticals, Inc. Leptino receptoriaus agonistinis antikūnas, skirtas kaulų masės didinimui subjektui, kuriam pasireiškia medžiagų apykaitos sutrikimas arba hipoleptinemija
EP3868743B8 (en) * 2018-10-11 2023-06-07 Sumitomo Chemical Company Limited Propylene oxide purification system and method for producing propylene oxide
WO2020160199A1 (en) 2019-01-31 2020-08-06 Siemens Healthcare Diagnostics Inc. Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof
US20220288169A1 (en) * 2019-05-24 2022-09-15 The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College Compositions and methods for the treatment and prevention of hypoglycemic complications
WO2021000251A1 (en) * 2019-07-02 2021-01-07 Shanghaitech University Antibody to leptin receptor
WO2021111156A1 (en) 2019-12-03 2021-06-10 Micron Technology, Inc. Cache architecture for a storage device
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
MX2023002995A (es) 2020-09-15 2023-05-19 Regeneron Pharma Uso de agonistas de lepr para el dolor.
LT4294257T (lt) 2021-02-22 2025-12-29 Regeneron Pharmaceuticals, Inc. Dalinės lipodistrofijos diagnostikos ir gydymo būdas
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
CN114456124B (zh) * 2021-12-30 2023-04-21 华南农业大学 一种新利司他半抗原、人工抗原、抗体及其制备方法和应用
KR20260025363A (ko) 2023-06-16 2026-02-24 리제너론 파아마슈티컬스, 인크. 의료 디바이스 패키징 및 관련 방법
WO2025075970A1 (en) 2023-10-02 2025-04-10 Regeneron Pharmaceuticals, Inc. Drug delivery device safety system
TW202602926A (zh) 2024-03-15 2026-01-16 美商美國禮來大藥廠 作為治療肥胖症之單一或組合療法之瘦素受體促效抗體
WO2025227054A1 (en) * 2024-04-25 2025-10-30 The Board Of Regents Of The University Of Texas System Monoclonal antibodies binding to leptin and uses thereof
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5856098A (en) 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US6482927B1 (en) 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US6977240B1 (en) * 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
EP0885299B1 (en) 1996-01-08 2005-10-26 Genentech, Inc. Ob receptor and ligands
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
AU2476301A (en) 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
AU1833197A (en) 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
CA2244693A1 (en) 1996-01-23 1997-07-31 Progenitor, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US5965521A (en) 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
JP2005506994A (ja) 2001-10-22 2005-03-10 アムジェン インコーポレイテッド ヒト脂肪組織萎縮症を処置するためのレプチンの使用および該処置のための素因決定方法
US20060165683A1 (en) * 2001-12-05 2006-07-27 Gerard Karsenty Methods and compositions for control of bone formation via modulation of sympathetic tone
FR2852397B1 (fr) 2003-03-10 2005-04-29 Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal.
DE10353593A1 (de) * 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
JPWO2005056602A1 (ja) * 2003-12-12 2008-03-06 中外製薬株式会社 アゴニスト活性を有する改変抗体のスクリーニング方法
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
US20100260772A1 (en) 2007-09-28 2010-10-14 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing diseases associated with low bone mass
WO2010054007A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
HRP20151188T4 (hr) 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
RU2013139267A (ru) 2011-02-10 2015-03-20 Рош Гликарт Аг Улучшенная иммунотерапия
LT2738259T (lt) 2011-02-25 2020-03-10 Regeneron Pharmaceuticals, Inc. Adam6 pelės
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
PT3865581T (pt) 2011-08-05 2024-10-04 Regeneron Pharma Murganhos da cadeia leve universal humanizada
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
KR20150023535A (ko) 2012-06-05 2015-03-05 리제너론 파마슈티칼스 인코포레이티드 공통 경쇄를 사용하여 완전한 인간 이중 특이적 항체를 만드는 방법
EP2895513B1 (en) 2012-09-12 2018-05-23 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
DK3108255T3 (da) 2014-02-18 2020-11-09 Inst Nat Sante Rech Med Fremgangsmåder og farmaceutiske sammensætninger til behandling af sygdomme medieret af nrp-1/obr-komplekssignalvejen
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
EA201991075A1 (ru) 2016-11-08 2019-10-31 Антигенсвязывающие белки, которые проявляют антагонизм в отношении лептинового рецептора
CN107760761A (zh) 2017-11-10 2018-03-06 江苏省农业科学院 一种加强瘦素激发lepr信号转导的方法
KR20200100089A (ko) 2017-12-18 2020-08-25 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체 및/또는 gp130에 결합하는 이중 특이적 항원 결합 분자 및 이의 사용 방법
LT3773713T (lt) 2018-04-06 2025-08-25 Regeneron Pharmaceuticals, Inc. Leptino receptoriaus agonistinis antikūnas, skirtas kaulų masės didinimui subjektui, kuriam pasireiškia medžiagų apykaitos sutrikimas arba hipoleptinemija

Also Published As

Publication number Publication date
IL258448A (en) 2018-05-31
BR112018007318A2 (en) 2018-10-23
US20250051465A1 (en) 2025-02-13
IL316563A (en) 2024-12-01
US10023644B2 (en) 2018-07-17
NZ780753A (en) 2025-06-27
PT3362477T (pt) 2022-03-02
MX2018004531A (es) 2018-09-12
TW202417497A (zh) 2024-05-01
US20220112293A1 (en) 2022-04-14
JP2018535948A (ja) 2018-12-06
KR20180070609A (ko) 2018-06-26
TWI752920B (zh) 2022-01-21
CL2019001434A1 (es) 2019-10-11
ES2908574T3 (es) 2022-05-03
CN108368177A (zh) 2018-08-03
AU2016338851B2 (en) 2023-08-10
DK3362477T3 (da) 2022-03-07
US20200031946A1 (en) 2020-01-30
MX2023000738A (es) 2023-02-13
LT3362477T (lt) 2022-03-10
IL258448B2 (en) 2023-08-01
RS63061B1 (sr) 2022-04-29
US12275792B2 (en) 2025-04-15
JP2024026230A (ja) 2024-02-28
WO2017066204A1 (en) 2017-04-20
TW202216785A (zh) 2022-05-01
TW201726737A (zh) 2017-08-01
IL300961A (en) 2023-04-01
JP7034068B2 (ja) 2022-03-11
JP7165225B2 (ja) 2022-11-02
HRP20220426T1 (hr) 2022-05-27
SMT202200125T1 (it) 2022-05-12
IL300961B1 (en) 2024-12-01
SI3362477T1 (sl) 2022-04-29
UA124419C2 (uk) 2021-09-15
EP3362477A1 (en) 2018-08-22
UY36942A (es) 2017-05-31
ZA201801975B (en) 2020-07-29
HUE058280T2 (hu) 2022-07-28
SG10201913432RA (en) 2020-03-30
JP2023002713A (ja) 2023-01-10
US20170101477A1 (en) 2017-04-13
PL3362477T3 (pl) 2022-05-02
US20180282420A1 (en) 2018-10-04
AU2016338851A1 (en) 2018-04-19
NZ780754A (en) 2025-06-27
MY187975A (en) 2021-11-05
PH12018500663A1 (en) 2018-10-01
CL2018000946A1 (es) 2018-12-14
JP2024042114A (ja) 2024-03-27
EP3362477B1 (en) 2022-01-05
NZ741097A (en) 2025-06-27
CN108368177B (zh) 2022-05-31
HRP20220426T8 (hr) 2022-06-10
CA3000215A1 (en) 2017-04-20
AU2023206125A1 (en) 2023-08-31
EP4071173A1 (en) 2022-10-12
CO2018003852A2 (es) 2018-07-10
JP7436603B2 (ja) 2024-02-21
KR20250069979A (ko) 2025-05-20
US10253102B2 (en) 2019-04-09
HK1254862A1 (zh) 2019-07-26
TWI824372B (zh) 2023-12-01
JP7699191B2 (ja) 2025-06-26
IL258448B1 (en) 2023-04-01
JP7759417B2 (ja) 2025-10-23
IL300961B2 (en) 2025-04-01
JP2021090461A (ja) 2021-06-17
EA201890928A1 (ru) 2018-09-28
US10618968B2 (en) 2020-04-14
US20180282421A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
PH12018500663A1 (en) Antigen-binding proteins that activate the leptin receptor
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CY1124896T1 (el) Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων
CY1124778T1 (el) Αντισωματα anti-asic1 και χρησεις αυτων
CY1125977T1 (el) Ενωσεiς που αλληλεπιδρουν με τη γλυκανη και μεθοδοι χρησης
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
CY1120471T1 (el) Αντισωματα κατα του cd70
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
CY1121637T1 (el) Αντι-dkk-1 αντισωματα
MX388410B (es) Modulacion de celulas mieloides estimulantes y no estimulantes.
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MX380414B (es) Polipeptidos biparatopicos que antagonizan la señalizacion wnt en celulas tumorales.
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
JOP20200343A1 (ar) بروتين ربط مولد ضد مضاد لـ steap1
CY1123275T1 (el) Μορια συνδεσης ειδικα για il-21 και χρησεις αυτων
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
MX2018011035A (es) Anticuerpos-anti-mica.
PH12017500331A1 (en) Antigen binding proteins that bind cxcr5
CY1123781T1 (el) Anti-tnf αλφα-αντισωματα και λειτουργικα θραυσματα αυτων
MX2017001959A (es) Anticuerpos especificos para mmp9.
EA201892063A1 (ru) МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn
MX2015016304A (es) Proteinas de union al antigeno del receptor de oncostatina m.
CY1124296T1 (el) Αντισωματα για il-17c